Abstract: A bio-processing system (100) is presented. The bio-processing system (100) includes one or more bio-processing units (110-114), one or more process supporting devices (116, 118), one or more sensors (120-132), and a bio-processing workflow controller (104) wirelessly coupled to at least one of the one or more bio-processing units (110-114), the one or more process supporting devices (116, 118), and the one or more sensors (120-132). The bio-processing workflow controller (104) includes a processor (202) configured to create a reconfigurable bio-processing workflow, and where the reconfigurable bio-processing workflow is representative of an arrangement of one or more of the one or more bio-processing units (110-114), the one or more process supporting devices (116, 118), and the one or more sensors (120-32) to perform at least one bio-processing operation.
Type:
Application
Filed:
April 18, 2018
Publication date:
April 30, 2020
Inventors:
Victor Jose, Andreas Axen, Klaus Gebauer, Veena B N Rao, Patric Fricking, Hanish Lakhani
Abstract: Multiple risers are provided to perform different steps in a biogas water wash process. The risers may include absorption risers, flashing risers, and stripping risers. In each riser, the inlets to provide fluids to the riser and outlets to remove fluids from the risers are provided at one end of the riser. Each riser may then be located substantially below grade such that the end with the inlets and outlets is accessible at or just above the ground level. The risers within each step of the water wash process may be connected in series, parallel, or a combination thereof. The risers may also be constructed of a polyethylene material to reduce cost and weight of the water wash system.
Abstract: Compositions including metal nano- and/or micro-particles in solution with photosynthetic bioproduct producing microorganisms. These light harvesting complexes increase growth rates and photosynthetic efficiency of the constituent microorganisms, reducing the light required for a specific production level, or increases production for a specific light level. Compositions including zero-valent iron nanoparticles (nZVIs) in solution with photosynthetic bioproduct producing microorganisms. The nZVIs cause increased growth, lipid production and fatty acid production.
Abstract: [Problem] To provide a cell preparation including mesenchymal stem cells (MSCs) having a high therapeutic effect. [Solution] A method for producing activated mesenchymal stem cells, including a step of culturing MSCs in a medium containing an activator that includes an extract from a mammalian fetal appendage as an active ingredient, using a cell culture carrier having a three-dimensional structure formed of a fiber is provided. A marker for a therapeutic effect of MSCs selected from the group consisting of p16ink4a, p14ARF, CDK4, CDK6, RB, and CD47, a method for determining a therapeutic effect using the maker, a method for determining suitability of MSCs to be treated with a treatment for enhancing a therapeutic effect of MSCs, a cell preparation including MSCs, and a method for producing the same are also provided.
Abstract: The present invention relates to a method of manufacturing a cell spheroid using three-dimensional bio-printing technology, and the cell spheroid may be used for preventing or treating vascular and endocrine diseases by including mesenchymal stem cells, induced pluripotent stem cells-derived cells, or the like as an active ingredient, or may be used as an in vitro drug testing model.
Abstract: This application provides constructs for use as complex cell systems of a desired shape and methods of preparing thereof. The constructs comprise cells contained within a biocompatible gel matrix deposited on a scaffold material optionally cut into defined patterns and impregnated with a crosslinking agent, wherein the biocompatible gel matrix crosslinks upon contact with the crosslinking agent on the scaffold. By stacking multiple alternating layers of the scaffold material cut into defined patterns and the biocompatible gel matrix deposited on the scaffold in defined patterns, complex 3D structures with features like embedded channels are be formed. These complex cell system constructs can be used as in vitro models of biological processes.
Abstract: The present invention relates to 2 cell-like stem cells and particularly, although not exclusively, the generation of such cells from pluripotent stem cells.
Type:
Application
Filed:
March 20, 2018
Publication date:
April 30, 2020
Inventors:
Vincenzo COSTANZO, Sina ATASHPAZGARGARI, Sara SAMADI SHAMS
Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.
Type:
Application
Filed:
October 25, 2019
Publication date:
April 30, 2020
Inventors:
Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O'CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
Abstract: This invention provides methods of generating natural killer (NK) cells and dendritic cells (DCs). The methods utilize human hemangioblasts as intermediate cells to generate the NK cells and DCs. In various embodiments, the methods do not require the use of stromal feeder layers.
Type:
Application
Filed:
October 31, 2019
Publication date:
April 30, 2020
Applicant:
ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Abstract: The present invention relates to a method for inducing the differentiation of hematopoietic stem cells or macrophages by using pluripotent stem cells, and a composition for inducing the differentiation. Specifically, the present invention relates to a composition for inducing the differentiation of hematopoietic stem cells comprising bone morphogenetic protein 4 (BMP4) in pluripotent stem cells, or a composition for inducing the differentiation of macrophages comprising BMP4 and a macrophage-colony stimulating factor (M-CSF), and a method for inducing the differentiation by using the compositions. The method for inducing the differentiation of the present invention is advantageous in that a differentiation method thereof is simple since only a few types of cytokine are used, and compared to conventional methods for inducing the differentiation, the efficiency of differentiation is improved tens of times or more and the yield of differentiated cells is high.
Type:
Application
Filed:
October 12, 2018
Publication date:
April 30, 2020
Inventors:
Jung Hyun Kim, Hyo Won Han, Hyang Hee Seo, Hyeong Jun Han
Abstract: This invention relates to a medium system and a method for ex vivo expansion of natural killer (NK) cells. This invention directly cultures Ficoll-separated PBMC by using immobilized anti-CD137 and RetroNectin, and uses OK-432 as a biological effector under the co-existence of GM-CSF, IL-4, IL-2, IL-15, and IL-21 for ex vivo activation and proliferation of NK cells, creating an efficient method for ex vivo expansion of NK cells. The expression rate of NK cells CD3-CD16+/CD56+ prepared by the method is as high as 92.5% or more. After 14 days of culture, NK cells can be expanded 1000 to 2000 times and have strong in vitro cytotoxic activity.
Abstract: Tissue processing devices are provided. The tissue processing devices can be used to process and transport tissue in a closed and continuous environment. The devices can be used for adipose tissue transfer, including autologous fat grafting.
Type:
Application
Filed:
December 31, 2019
Publication date:
April 30, 2020
Inventors:
Kai-Roy Wang, Aaron Barere, Evan J. Friedman, Sangwook Park
Abstract: The present invention relates to a preparation method of a spheroid using human-derived cardiac stem cells and a therapeutic use for ischemic heart disease using the myocardial regeneration effect thereof. The spheroid using the cardiac stem cells provided in the present invention has excellent myocardial differentiation ability and regenerative therapeutic ability as compared to existing cardiac stem cells, and thus may be used for the treatment of ischemic heart disease such as myocardial infarction.
Abstract: The present disclosure relates to a medium composition for enhancing proliferation of stem cells, comprising ethionamide, and a use thereof. It is possible, according to the present disclosure, to mass-produce highly-efficient next-generation stem cells through a simple and safe method of controlling a culturing environment, without using genetic modification or viral vectors, etc.
Type:
Application
Filed:
September 28, 2017
Publication date:
April 30, 2020
Inventors:
Duk Lyul NA, Jong Wook CHANG, Hyo Jin SON, Su Hyeon MYEONG
Abstract: Embodiments of the invention include systems and media for mammalian cell culture that enhance cell viability which enables biological assays and quantitative studies in tissues such as skin explants. Certain embodiments may be used in coordination with each other or may be practiced separately. An exemplary embodiment of the invention is a culture medium that includes Dulbecco's Modified Eagle's Medium, X-VIVO medium, and subcutaneous adipocyte medium. In one embodiment the culture medium includes approximately 30-60% Dulbecco's Modified Eagle's Medium by volume, approximately 30-60% X-VIVO medium by volume, and approximately 2.5-15% subcutaneous adipocyte medium by volume. Certain embodiments of the culture medium can also include recombinant human stem cell factor. Embodiments of the invention disclosed here are not limited to the brands described and encompass equivalents, as well as combinations, of the individual chemical components that make up the media described herein.
Type:
Application
Filed:
October 21, 2019
Publication date:
April 30, 2020
Inventors:
CAROLE A. OSKERITZIAN, ALENA P. CHUMANEVICH
Abstract: Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain high fidelity under reduced incorporation times, as well as methods and kits using the same.
Abstract: The present invention provides engineered DNA polymerase polypeptides and compositions thereof, as well as polynucleotides encoding the engineered DNA polymerase polypeptides. The invention also provides methods for use of the compositions comprising the engineered DNA polymerase polypeptides for diagnostic and other purposes.
Type:
Application
Filed:
October 28, 2019
Publication date:
April 30, 2020
Inventors:
Mathew G. Miller, Vesna Mitchell, Jovana Nazor, Donald S. Baskerville, Nikki Dellas, David Elgart, Jonathan Vroom, Sandy M. Gomes, Nandhitha Subramanian, Ericka Bermudez
Abstract: Provided are engineered DNA polymerases exhibiting modified functionality, and polynucleotides encoding same. Modified features include: (1) reduced catalytic activity in the presence of magnesium ions and/or (2) reduced affinity for primed template nucleic acid molecules in the absence of cognate nucleotide, and an ability to discriminate between cognate and non-cognate nucleotides under low salt conditions. Sequencing By Bindingâ„¢ procedures employing the engineered polymerases have certain advantages. The engineered polymerases can have other uses as well.
Type:
Application
Filed:
January 9, 2020
Publication date:
April 30, 2020
Applicant:
Omniome, inc.
Inventors:
Pinar IYIDOGAN, Mark C. WALLEN, Ying L. LIU, Kandaswamy VIJAYAN
Abstract: Provided is a dielectric calibration technique using C2c1 endonuclease. The dielectric calibration technique is characterized by being especially applicable to eukaryotic cells, for example, to mammalian cells.
Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas13b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.
Type:
Application
Filed:
March 15, 2018
Publication date:
April 30, 2020
Inventors:
David Benjamin Turitz Cox, Neena Pyzocha, Feng Zhang
Abstract: The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within the human PCSK9 gene. The present invention also encompasses methods for using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of cholesterol-related disorders, such as hypercholesterolemia. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating cholesterol-related disorders, such as hypercholesterolemia.
Type:
Application
Filed:
April 20, 2018
Publication date:
April 30, 2020
Applicant:
Precision BioSciences, Inc.
Inventors:
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Janel Lape
Abstract: The present invention relates to glucoamylase variants having an increase in raw starch activity compared to the guy-coamylase disclosed as SEQ ID NO: 2, comprising one or more modifications in the catalytic domain and/or one or more modifications in the starch binding domain selected from: a) at least one, preferably at least two, preferably at least three, preferably at least four of: V18M, T43K, N112L, T116R, A117Q, G120S, A271F, Y295W, Q318Y; and/or b) Introducing at least three, preferably at least four substitutions selected from the group: S458C, S458SCGG, S458SGGC, A493V, A518K, E520Q, N527M, S540K, R, S(G)546P, T(V)549W, N503R, N539R+I541Y+T543V+A545S+S546GCGV+G547S+S548T+T549A. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Type:
Application
Filed:
April 10, 2018
Publication date:
April 30, 2020
Applicant:
NOVOZYMES A/S
Inventors:
Tomoko Namoto, Noriko Tsutsumi, Keiichi Ayabe, Zhengfang Kang
Abstract: Animal feed or animal feed additives comprising one or more polypeptides having lysozyme activity. Polypeptides having lysozyme activity, polynucleotides encoding the polypeptides nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Application
Filed:
May 11, 2018
Publication date:
April 30, 2020
Applicant:
Novozymes A/S
Inventors:
Ye Liu, Ming Li, Kirk Matthew Schnorr, Peter Bjarke Olsen
Abstract: The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
Type:
Application
Filed:
December 23, 2019
Publication date:
April 30, 2020
Applicant:
Genzyme Corporation
Inventors:
Rahul Godawat, Daniel Cummings, Veena Warikoo
Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.
Type:
Application
Filed:
July 6, 2017
Publication date:
April 30, 2020
Applicant:
MERZ PHARMA GMBH & CO. KGAA
Inventors:
JĂ¼rgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LĂ“PEZ DE LA PAZ, Daniel SCHEPS
Abstract: Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and/or prevention of inflammation, in particular overweight and/or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.
Type:
Application
Filed:
April 3, 2018
Publication date:
April 30, 2020
Applicants:
TARGEDYS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE ROUEN
Abstract: This invention provides chromatographic methods for the purification of a cystathionine ?-Synthase (CBS) protein, particularly truncated variants thereof and compositions and pharmaceutical compositions prepared therefrom.
Type:
Application
Filed:
January 10, 2020
Publication date:
April 30, 2020
Inventors:
Richard Carrillo, Jan P. Kraus, Tomas Majtan, David Naveh
Abstract: The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering a polynucleotide sequence encoding an MCM polypeptide.
Abstract: Disclosed herein are methods of producing hexoses from saccharides by enzymatic processes. The methods utilize fructose 6-phosphate and at least one enzymatic step to convert it to a hexose.
Type:
Application
Filed:
January 8, 2020
Publication date:
April 30, 2020
Applicant:
BONUMOSE LLC
Inventors:
Daniel Joseph WICHELECKI, Edwin O. ROGERS
Abstract: Devices, systems, and kits for cell electroporation are provided. A device includes a first electrode, a second electrode, and an electroporation zone therebetween where an electrical potential difference applied to the first and second electrodes generates an electric field in the electroporation zone sufficient to electroporate at least a subset of the cells in the flow path. Methods of introducing a composition into at least a portion of a plurality of cells using the devices, systems, and kits of the invention are also provided.
Type:
Application
Filed:
October 28, 2019
Publication date:
April 30, 2020
Inventors:
Paulo Andres GARCIA, Jessica SIDO, James HEMPHILL, Rameech MCCORMACK, Harrison BRALOWER
Abstract: The present invention provides a method for producing a target nucleic acid molecule, including: (a) providing a double-stranded nucleic acid molecule including a target sequence region, a first flanking sequence region linked to the 5? end of the target sequence region and containing one or more deaminated bases, and a second flanking sequence region linked to the 3? end of the target sequence region; and (b) incubating the nucleic acid molecule and an endonuclease specific for the deaminated bases to remove the first flanking sequence region ranging from the deaminated base closest to the 5? end of the target sequence region to the 5? end of the nucleic acid molecule. The present invention also provides a composition for producing a target nucleic acid molecule including the double-stranded nucleic acid molecule and a deaminated base-specific endonuclease.
Type:
Application
Filed:
February 20, 2018
Publication date:
April 30, 2020
Inventors:
Sung Hoon KWON, Jung Min KIM, Jin Sung NOH, Hui Ran YEOM, Tae Hoon RYU
Abstract: Systems, methods, and compositions provided herein relate to preparation of beads encapsulating biomolecules for performing sequential reactions on the biomolecules. Some embodiments include preparation of nucleic acid reactions within the bead, wherein the bead includes pores that allow diffusion of molecules into or out of the beads while retaining other molecules of interest.
Type:
Application
Filed:
October 24, 2019
Publication date:
April 30, 2020
Inventors:
Steven Norberg, Dmitry Pokholok, Ramesh Ramji, Frank J. Steemers, Fan Zhang
Abstract: A fixed tube of a nucleic acid extraction component and a nucleic acid extraction component. The nucleic acid extraction component includes a membrane column, which is fitted over the fixed tube. The fixed tube has a tube body, a tube opening, and a bottom. The tube body extends along a first direction. The end of the tube opening distal from the tube body has a protrusion which protrudes along a second direction, the first direction being vertical to the second direction. The bottom and the tube opening are respectively connected to two opposite sides of the tube body. The bottom has a shoulder and the shoulder of the bottom is connected to the membrane column.
Abstract: Provided is a plasmid library comprising a DNA insertion site and two barcode sequences located upstream and downstream of the site. The combinations of two barcode sequences of any two plasmids selected from the library are different. Also provided is a method for high-throughput paired-end sequencing of an inserted DNA using the plasmid library.
Abstract: The disclosure provides methods for haplotype phasing and meta-genomics assemblies. The disclosure provides a streamlined method for accomplishing these tasks, such that intermediates need not be labeled by an affinity label to facilitate binding to a solid surface. The disclosure also provides methods and compositions for the de novo generation of scaffold information, linkage information, and genome information for unknown organisms in heterogeneous metagenomic samples or samples obtained from multiple individuals. Practice of the methods can allow de novo sequencing of entire genomes of uncultured or unidentified organisms in heterogeneous samples, or the determination of linkage information for nucleic acid molecules in samples comprising nucleic acids obtained from multiple individuals.
Type:
Application
Filed:
September 5, 2019
Publication date:
April 30, 2020
Inventors:
Richard E. Green, Paul Hartley, Christopher John Troll, Ei Ei Min
Abstract: Provided herein are compositions and methods for analyzing nucleic acids in a sample. Compositions include simple barcode sets having reduced DNA sequencing instrument-specific error rates. Methods include methods to deconvolute sequence reads from different samples.
Type:
Application
Filed:
June 21, 2018
Publication date:
April 30, 2020
Inventors:
Momchilo VUYISICH, Jason GANS, Patrick CHAIN, Andrew HATCH
Abstract: Provided herein is a method of constructing a high throughput sequencing library for use in detecting chromosome copy number variation comprising mainly the following steps: (1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme; (2) end-filling and adding poly-adenine at the 3?end of the fragmented DNAs; (3) connecting the end-filled DNAs having a 3?end poly-adenine with sequencing linkers to obtain connected products; (4) purifying the connected products to obtain the sequencing library; wherein steps (1)-(3) are performed in a single reaction tube. Also provided is a kit for constructing a sequencing library for use in detecting chromosome copy number variation.
Abstract: The present disclosure relates to methods of joining three or more double-stranded (ds) or single-stranded (ss) DNA molecules of interest in vitro or in vivo. The method allows the joining of a large number of DNA fragments, in a deterministic fashion. It can be used to rapidly generate nucleic acid libraries that can be subsequently used in a variety of applications that include, for example, genome editing and pathway assembly. Kits for performing the method are also disclosed.
Type:
Application
Filed:
October 31, 2019
Publication date:
April 30, 2020
Inventors:
Erik Jedediah Dean, Kedar Patel, Aaron Miller, Kunal Mehta, Philip Weyman
Abstract: A presumption-free pipeline is provided that employs experimental and analytic modules to profile samples, including clinical samples, regardless of the complexity and abundance. The experimental and analytic modules can work independently of each other if the user so desired. The experimental module for ultra-sensitive DNA/RNA extraction and sequencing can be used to extract information from any samples to feed into analytical pipelines chosen by the user. Alternatively, the analytic module for universal species detection can be fed with data generated with other experimental pipelines and different sequencing platforms.
Abstract: Provided is a PCR primer pair, comprising: a first primer and a second primer, wherein the first primer comprises a first specific sequence and a first random sequence; the first specific sequence is located on 3? end of the first primer, and the first random sequence is located on 5? end of the first primer; the second primer comprises a second specific sequence and a second random sequence, the second specific sequence is located on 3? end of the second primer, and the second random sequence is located on 5? end of the second primer; moreover, the first specific sequence and the second specific sequence are an upstream primer and a downstream primer directed to a target sequence respectively, and the first random sequence and the second random sequence are inverse complementary.
Type:
Application
Filed:
June 20, 2017
Publication date:
April 30, 2020
Inventors:
Lin Yang, Ya Gao, Guodong Huang, Yicong Wang, Yuqian Wang, Yanyan Zhang, Fang Chen, Na Zhong, Hui Jiang, Xun Xu
Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention trelates to a CRISPR-Cas system for a Labyrinthulomycetes host cell.
Abstract: The present invention relates to chemically-modified polynucleotides of formula (I): 5?-CONS-SEQ.ID.n-CONS-3? (I) containing one or more modified pyrimidines and at least one inverted nucleotide repeat, and to the method for producing the same.
Type:
Application
Filed:
September 12, 2019
Publication date:
April 30, 2020
Inventors:
Alexander Henning ULRICH, Vinicius BASSANEZE, Arthur Andrade NERY, Jose Eduardo KRIEGER
Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
Type:
Application
Filed:
May 24, 2019
Publication date:
April 30, 2020
Applicant:
Alnylam Pharmaceuticals, Inc.
Inventors:
Akin Akinc, Gregory Hinkle, Martin A. Maier, James Butler, Jingxuan Liu
Abstract: The subject invention provides a novel SELEX strategy for isolating cross-reactive aptamers that recognize a core structure of a small-molecule family and bind to each structurally-similar molecule in said family. The subject invention also provides methods, assays, and products for detecting small-molecule targets of the family in a sample in both clinical and field settings. Such method is based on an aptamer sensor that reports the presence of small-molecule targets via a sensitive colorimetric signal for naked-eye detection. The subject invention further provides exonuclease-based methods for generating structure-switching aptamers from fully folded aptamers and developing electrochemical aptamer-based (E-AB) sensors for rapid and sensitive detection of synthetic cathinones.
Type:
Application
Filed:
October 30, 2018
Publication date:
April 30, 2020
Applicant:
The Florida International University Board of Trustees
Inventors:
Weijuan Yang, Haixiang Yu, Yingzhu Liu, Yi Xiao
Abstract: Provided herein are aptamers for binding lipoproteins, systems for binding lipoproteins, and methods of detecting lipoproteins in a sample. The aptamers are useful for detecting the levels of lipoproteins in a biological sample and selectively detecting LDL particles in the presence of HDL particles. The aptamers can also be used as therapeutic agents against various diseases.
Type:
Application
Filed:
July 6, 2018
Publication date:
April 30, 2020
Inventors:
Eshwar INAPURI, Anup SINGH, Gregory Allen PENNER
Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.